ArticleChemical & biomedical imaging2024
Cervical Cancer Tissue Analysis Using Photothermal Midinfrared Spectroscopic Imaging.
Article in Chemical & biomedical imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Imaging from Macro to Nanoscale: Multimodal Advances in Chemical and Biomedical Imaging.Chemical & biomedical imaging · 2026Review
- Deep learning assisting the surgical management of gynecologic cancers.Current opinion in oncology · 2026Review
- From Image-Guided Surgery to Computer-Assisted Real-Time Diagnosis with Hyperspectral and Multispectral Imaging: A Systematic Review in Gynecologic Oncology.Diagnostics (Basel, Switzerland) · 2026Review
- Efficient 3D Biomedical Image Segmentation by Parallelly Multiscale Transformer-CNN Aggregation Network.Chemical & biomedical imaging · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Hyperspectral photothermal mid-infrared spectroscopic imaging (HP-MIRSI) is an emerging technology with promising applications in cervical cancer diagnosis and quantitative, label-free histopathology. This study pioneers the application of HP-MIRSI to the evaluation of clinical cervical cancer tissues, achieving excellent tissue type segmentation accuracy of over 95%. This achievement stems from an integrated approach of optimized data acquisition, computational data reconstruction, and the application of machine learning algorithms. The results are statistically robust, drawing from tissue samples of 98 cervical cancer patients and incorporating over 40 million data points. Traditional cervical cancer diagnosis methods entail biopsy, staining, and visual evaluation by a pathologist. This process is qualitative, subject to variations in staining and subjective interpretations, and requires extensive tissue processing, making it costly and time-consuming. In contrast, our proposed alternative can produce images comparable to those from histological analyses without the need for staining or complex sample preparation. This label-free, quantitative method utilizes biochemical data from HP-MIRSI and employs machine-learning algorithms for the rapid and precise segmentation of cervical tissue subtypes. This approach can potentially transform histopathological analysis by offering a more accurate and label-free alternative to conventional diagnostic processes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.